Reference intervals for holotranscobalamin and total vitamin B12 in 6-12-year-old children in Norway: the Health

Martin Frank Strand1, Helle Borgstrøm Hager2, Per Morten Fredriksen3,4

  • 1School of Health Sciences, Kristiania University College, Oslo, Norway.

Insights

This study establishes new vitamin B12 (B12) reference ranges for children aged 6-12. These age-specific vitamin B12 and holotranscobalamin (holoTC) values will improve deficiency diagnosis in pediatric populations.

Area of Science:

  • Clinical Chemistry
  • Pediatric Endocrinology
  • Nutritional Science

Background:

  • Vitamin B12 (B12) is crucial for DNA synthesis and neurological health.
  • B12 is transported via haptocorrin and transcobalamin, measured as total B12 and holotranscobalamin (holoTC).
  • Holotranscobalamin (holoTC) better reflects B12 availability for tissue uptake, but pediatric reference values are scarce.

Purpose of the Study:

  • To establish age-specific pediatric reference intervals (RIs) for total B12 and holoTC in healthy school children.
  • To provide clinicians with essential data for accurate interpretation of B12 status in children aged 6-12 years.

Main Methods:

  • Blood samples from 1320 healthy Norwegian children (ages 6-12) were analyzed.
  • Total B12 and holoTC levels were determined using chemiluminescent microparticle immunoassay.
  • Age-specific RIs were calculated using the nonparametric method (2.5th and 97.5th percentiles).

Main Results:

  • Established 95% RIs for total B12: 295-1066 pmol/L (6-8 years) and 249-879 pmol/L (9-12 years).
  • Established 95% RIs for holoTC: ≥56 pmol/L (6-8 years) and ≥37 pmol/L (9-12 years).

Conclusions:

  • Age-specific reference intervals for total B12 and holoTC in children aged 6-12 years have been determined.
  • These new RIs will enhance the accurate diagnosis and management of vitamin B12 status in pediatric patients.

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...